Chronic daily supplementation with 75 mg of resveratrol for 6 weeks resulted in a 23% increase in flow-mediated dilatation compared with placebo in healthy obese adults (P=0.021).
RCT (n=28)
double-blind
randomized
Effect estimate: 23% increase
p-value: p=0.021
BACKGROUND: We have previously demonstrated acute dose-dependent increases of flow-mediated dilatation (FMD) in the brachial artery after resveratrol consumption in mildly hypertensive, overweight/obese adults. Resveratrol supplementation has also been shown to increase cerebral blood flow acutely, without affecting cognition. OBJECTIVES: To evaluate the effects of chronic resveratrol supplementation on both FMD and cognitive performance. METHOD: Twenty-eight obese but otherwise healthy adults (BMI: 33.3 ± 0.6 kg/m) were randomized to take a single 75 mg capsule of trans-resveratrol (Resvida) or placebo daily for 6 weeks each in a double-blind crossover supplementation trial. Blood pressure, arterial compliance, FMD, and performance on the Stroop Color-Word Test were assessed at the end of each 6-week intervention period while fasted and at least 18 h after taking the last daily capsule. An additional capsule of the same supplement was then taken. FMD assessment was repeated 1 h later. RESULTS: Chronic resveratrol supplementation for 6 weeks was well tolerated and resulted in a 23% increase in FMD compared with placebo (P=0.021, paired t-test). The extent of increase correlated negatively with baseline FMD (r=-0.47, P=0.01). A single dose of resveratrol (75 mg) following chronic resveratrol supplementation resulted in a 35% greater acute FMD response than the equivalent placebo supplementation. These FMD improvements remained significant after adjusting for baseline FMD. Blood pressure, arterial compliance, and all components of the Stroop Color-Word Test were unaffected by chronic resveratrol supplementation. CONCLUSION: Daily resveratrol consumption was well tolerated and has the potential to maintain healthy circulatory function in obese adults.
Wong et al. (Thu,) conducted a rct in obese but otherwise healthy adults (n=28). trans-resveratrol vs. placebo was evaluated on flow-mediated dilatation (FMD) and cognitive performance (23% increase, p=0.021). Chronic daily supplementation with 75 mg of resveratrol for 6 weeks resulted in a 23% increase in flow-mediated dilatation compared with placebo in healthy obese adults (P=0.021).